Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to $12.1 million.

  • Cardiff Oncology's Operating Expenses fell 526.4% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.2 million, marking a year-over-year increase of 1508.7%. This contributed to the annual value of $49.3 million for FY2024, which is 748.15% up from last year.
  • As of Q3 2025, Cardiff Oncology's Operating Expenses stood at $12.1 million, which was down 526.4% from $14.9 million recorded in Q2 2025.
  • In the past 5 years, Cardiff Oncology's Operating Expenses ranged from a high of $14.9 million in Q2 2025 and a low of $5.5 million during Q1 2021
  • In the last 5 years, Cardiff Oncology's Operating Expenses had a median value of $11.1 million in 2024 and averaged $10.9 million.
  • As far as peak fluctuations go, Cardiff Oncology's Operating Expenses skyrocketed by 10217.63% in 2022, and later tumbled by 821.59% in 2024.
  • Cardiff Oncology's Operating Expenses (Quarter) stood at $9.7 million in 2021, then fell by 1.44% to $9.5 million in 2022, then rose by 10.17% to $10.5 million in 2023, then rose by 21.31% to $12.7 million in 2024, then fell by 4.94% to $12.1 million in 2025.
  • Its Operating Expenses was $12.1 million in Q3 2025, compared to $14.9 million in Q2 2025 and $14.5 million in Q1 2025.